NCT06892106 (SCIMBIONT) is a clinical trial in Spinal Cord Injury, sponsored by Centro Academico Clínico Egas Moniz Health Alliance.

Who is sponsoring NCT06892106?

NCT06892106 is sponsored by Centro Academico Clínico Egas Moniz Health Alliance.

What condition does NCT06892106 study?

NCT06892106 studies Spinal Cord Injury, Gut Dysbiosis, Immune Dysfunction.

Is NCT06892106 still recruiting?

NCT06892106 is currently completed. Last updated 24 March 2025.

Last reviewed 2025-03-24 · How we verify

NCT06892106: SCIMBIONT

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Gut Dysbiosis in Spinal Cord Injury Rehabilitation

Completed Last updated 24 March 2025

What this trial tests

trial in Spinal Cord Injury in 106 participants. Completed in 16 October 2023.

Timeline

1 May 2021

Primary endpoint
16 October 2023

16 October 2023

Quick facts

Lead sponsor	Centro Academico Clínico Egas Moniz Health Alliance
Status	Completed
Study type	OBSERVATIONAL
Enrollment	106
Start date	1 May 2021
Primary completion	16 October 2023
Estimated completion	16 October 2023
Sites	1 location across Portugal

Conditions studied

Spinal Cord Injury — all drugs for Spinal Cord Injury →
Gut Dysbiosis — all drugs for Gut Dysbiosis →
Immune Dysfunction — all drugs for Immune Dysfunction →

Sponsor

Centro Academico Clínico Egas Moniz Health Alliance

Who can join

18 and older, any sex, with Spinal Cord Injury or Gut Dysbiosis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The goal of this study is to investigate the role of gut microbiota, and related immune biomarkers and metabolites, in the functional recovery of spinal cord injury patients during the subacute phase. The main question it aims to answer is: How does gut microbiota dysbiosis impact functional recovery in subacute SCI patients, in a way that future targeted probiotic interventions may improve SCI outcomes?

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Spinal Cord Injury

Currently open trials in the same condition.

NCT07429305 — Combined Tibial Nerve Stimulation and Standing for People With SCI · NA · recruiting
NCT06410001 — CE-STAND: Cervical Epidural STimulation After Neurologic Damage · Phase 1, PHASE2 · recruiting
NCT05926596 — Leg Stretching Using an Exoskeleton on Demand for People With Spasticity · NA · recruiting
NCT06839300 — The International Spinal Cord Injury Blood Biomarker Longitudinal Evaluation (I-SCRIBBLE) Study · recruiting
NCT07036107 — A Trial on the Clinical and Socioeconomic Impact of Wearable Exoskeletons for Spinal Cord Injury Rehabilitation in the S · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06892106 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Centro Academico Clínico Egas Moniz Health Alliance
Last refreshed: 24 March 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06892106.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing